Inotrem raises Europe's biggest Series A this year

An early-stage French company focused on developing a new treatment for sepsis says it has raised the largest series A financing in Europe to date in 2014. Inotrem, which was set up in 2013 around research work done at the University of Lorraine Medical School in Nancy, has completed a €18m fundraising led by Edmond de Rothschild Investment Partners and Sofinnova Partners.

Inotrem is developing a small molecule TREM-1 (triggering receptor expressed on myeloid cells-1) inhibitor that has shown activity in sepsis animal models